Brief: 89Bio Announces Positive Long-Term Data From The ENLIVEN Phase 2B Trial Of Pegozafermin In Patients With Nonalcoholic Steatohepatitis
27/11/2023 14:39
Nov 27 (Reuters) - 89Bio Inc ETNB.O :
* 89BIO ANNOUNCES NEW POSITIVE LONG-TERM DATA FROM THE
ENLIVEN
PHASE 2B TRIAL OF PEGOZAFERMIN IN PATIENTS WITH NONALCOHOLIC
STEATOHEPATITIS (NASH)
* 89BIO INC - PEGOZAFERMIN CONTINUED TO DEMONSTRATE A
FAVORABLE
SAFETY AND TOLERABILITY PROFILE CONSISTENT WITH PREVIOUSLY
REPORTED DATA
* 89BIO INC - PEGOZAFERMIN IS ADVANCING INTO A PHASE 3 TRIAL
FOR
NASH AND IS BEING STUDIED IN PHASE 3 ENTRUST TRIAL FOR SHTG
Source text for Eikon: ID:nGNXj4V8r
Further company coverage: ETNB.O
((Reuters.Briefs@thomsonreuters.com;))